Disbanding and placing AxelMedica into special liquidation. The growth strategy in our healthcare domain may be affected; many receivables are expected to become uncollectible due to the dissolution. Revenue during the dissolution period is expected to be near zero, and after liquidation, the subsidiary will be excluded from the group consolidated accounts. There may be a possibility of recording extraordinary losses in future consolidated results. The outlook for FY2027 is undecided.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3624","jir_company_name":"Axelmark Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/3624-20260917-02.pdf","jir_short_summary":"Disbanding and placing AxelMedica into special liquidation. The growth strategy in our healthcare domain may be affected; many receivables are expected to become uncollectible due to the dissolution. Revenue during the dissolution period is expected to be near zero, and after liquidation, the subsidiary will be excluded from the group consolidated accounts. There may be a possibility of recording extraordinary losses in future consolidated results. The outlook for FY2027 is undecided.","jir_summary":"### Section Heading\nThis release states that we have resolved to dissolve our wholly-owned subsidiary AxelMedica Co., Ltd. and liquidate it through a special liquidation process, and that we will transfer and rebuild the Beauty & Wellness business conducted by the subsidiary. Due to the risk of uncollectible receivables and tightening finances, dissolution and liquidation will be carried out. Revenue from this business is expected to be nearly zero during the liquidation, and will be excluded from the group in the future.\n\n### Section 2 Heading\nLooking ahead, AxelMedica will be excluded from the consolidated scope, and there is a possibility of recording extraordinary losses in the consolidated results for the fiscal year ending September 2026. Most of the loans are expected to be uncollectible, and additional loan-loss provisions are anticipated. The progress of the growth strategy in the healthcare sector may be affected, and it is expected to take some time to resume the business; earnings guidance for FY2027 is not yet determined.","jir_financial_highlights":"Loans: 112,500 thousand yen (Risk of insolvency\/uncollectible receivables)\nNet assets (AxelMedica): \u25b2104,779,932 thousand yen (As of end-August 2026)\nSales (AxelMedica): 0 (Zero over the past 2 years)\nEstablishment date: September 2, 2024 ( - )","jir_category":"","jir_hashtags":"#AxelMark, #BusinessRestructuringDissolution","jir_key_figures":"Loans 112,500 thousand yen (risk of uncollectible receivables)\nAxelMedica net assets \u25b2104,779,932 thousand yen (as of end-August 2026)\nSales 0 (past 2 years)","jir_meta_title":"AxelMark: Announcement of Consolidated Subsidiary Dissolution and Special Liquidation Policy | September 2026","jir_meta_description":"AxelMark announces the dissolution and special liquidation of its subsidiary AxelMedica. It discloses concerns about stagnation in healthcare growth strategy, receivables collection risk, zero revenue during liquidation, potential extraordinary losses, and other future financial impacts.","jir_og_title":"AxelMark: Substantial Disbandment and Special Liquidation of Subsidiary | Sep 2026","jir_og_description":"AxelMark decides to dissolve and liquidate its consolidated subsidiary. Summary of key investor points: receivables collection risk, expected zero revenue, and potential future financial impacts.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":61292,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-114803","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n